PHARMA
New Alzheimer’s Drugs Developed By Eisai & Biogen Idec
Eisai and Biogen Idec are developing two new Alzheimer's drugs at Phase II clinical trials, E2609 and BAN2401.
WuXi Constructs New Facility In Changzhou
Upon completion, the Changzhou facility will triple WuXi's current capacity and employ more than 1,500 employees.
Eisai, Uni Of Tsukuba To Find Treatments For IBD
The private-public partnership between Eisai and the University of Tsukuba will focus on developing drugs and diagnostics for inflammatory bowel disease.
WuXi Begins Construction Of New Facility In Philadelphia
WuXi PharmaTech's intended 45,000 square feet facility will be for the manufacture of cell-based therapeutics.
Fosun Pharma Granted License For TB Alliance Drug
The public-private partnership between the Gates Foundation, TB alliance and Fosun Pharma aims to develop and commercialize a new TB drug in China.
Sinovac Receives Grant To Build HFMD Vaccine Plant
Vaccine manufacturer Sinovac has been awarded a US$9.6 million grant for the construction of a hand, foot and mouth disease vaccine facility.
Chindex To Merge With Fosun Pharma At Higher Share Price
Fosun Pharma and TPG increase their bid for Chindex from US$19.50 to US$24.00 per share.
Sanofi Pasteur Concludes Phase III Trial For Dengue Vaccine
The Phase III trial, which enrolled more than 10,000 children in Asia, showed that vaccination led to a 56 percent reduction in dengue cases.
Mucosis Raises US$6.9 Million In Deal With Changchun BCHT
The investment gives Changchun BCHT the license to Mucosis' RSV candidate vaccine and the Mimopath® platform.
